JP2013525293A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525293A5
JP2013525293A5 JP2013504278A JP2013504278A JP2013525293A5 JP 2013525293 A5 JP2013525293 A5 JP 2013525293A5 JP 2013504278 A JP2013504278 A JP 2013504278A JP 2013504278 A JP2013504278 A JP 2013504278A JP 2013525293 A5 JP2013525293 A5 JP 2013525293A5
Authority
JP
Japan
Prior art keywords
alkyl
amino
phenyl
fluoro
difluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013504278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525293A (ja
JP5886271B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/055917 external-priority patent/WO2011128407A2/en
Publication of JP2013525293A publication Critical patent/JP2013525293A/ja
Publication of JP2013525293A5 publication Critical patent/JP2013525293A5/ja
Application granted granted Critical
Publication of JP5886271B2 publication Critical patent/JP5886271B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013504278A 2010-04-16 2011-04-14 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン含有組合せ品 Expired - Fee Related JP5886271B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10160109 2010-04-16
EP10160109.4 2010-04-16
PCT/EP2011/055917 WO2011128407A2 (en) 2010-04-16 2011-04-14 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Publications (3)

Publication Number Publication Date
JP2013525293A JP2013525293A (ja) 2013-06-20
JP2013525293A5 true JP2013525293A5 (https=) 2014-06-19
JP5886271B2 JP5886271B2 (ja) 2016-03-16

Family

ID=44144895

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013504278A Expired - Fee Related JP5886271B2 (ja) 2010-04-16 2011-04-14 置換2,3−ジヒドロイミダゾ[1,2−c]キナゾリン含有組合せ品

Country Status (24)

Country Link
US (1) US20130184270A1 (https=)
EP (1) EP2558126A2 (https=)
JP (1) JP5886271B2 (https=)
KR (1) KR20130098155A (https=)
CN (1) CN102958540B (https=)
AU (1) AU2011240003A1 (https=)
BR (1) BR112012026480A2 (https=)
CA (1) CA2796253A1 (https=)
CL (1) CL2012002887A1 (https=)
CO (1) CO6620036A2 (https=)
CR (1) CR20120524A (https=)
CU (1) CU20120150A7 (https=)
DO (1) DOP2012000269A (https=)
EA (1) EA201201414A8 (https=)
EC (1) ECSP12012261A (https=)
IL (1) IL222356A0 (https=)
MA (1) MA34158B1 (https=)
MX (1) MX2012012064A (https=)
PE (1) PE20130191A1 (https=)
PH (1) PH12012502069A1 (https=)
SG (1) SG184550A1 (https=)
TN (1) TN2012000493A1 (https=)
WO (1) WO2011128407A2 (https=)
ZA (1) ZA201208616B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) * 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
WO2014160034A1 (en) * 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase-1 modulators and methods of use thereof
CU24400B1 (es) 2013-04-08 2019-04-04 Bayer Pharma AG Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
WO2016142312A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
WO2016142313A1 (en) * 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines
US10844066B2 (en) 2016-03-08 2020-11-24 Bayer Pharma Aktiengesellschaft 2-amino-N-[7-methoxy-2, 3-dihydroimidazo-[1,2-c] quinazolin-5-yl] pyrimidine-5-carboxamides
WO2019002068A1 (en) 2017-06-28 2019-01-03 Bayer Consumer Care Ag COMBINATION OF A PI3K INHIBITOR AND AN ANDROGEN RECEPTOR ANTAGONIST
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
ATE411996T1 (de) * 2002-09-30 2008-11-15 Bayer Healthcare Ag Kondensierte azolpyrimidinderivate
JP4323793B2 (ja) 2002-12-16 2009-09-02 キヤノン株式会社 ズームレンズ及びそれを有する光学機器
DE102004064002B4 (de) 2004-08-04 2019-05-09 Continental Automotive Gmbh System zum Überwachen einer Sensorvorrichtung
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
MX2010011314A (es) * 2008-04-14 2010-11-12 Ardea Biosciences Inc Composiciones y metodos de preparacion y uso de las mismas.
EP2168583A1 (en) * 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma

Similar Documents

Publication Publication Date Title
JP2013525293A5 (https=)
US12234221B2 (en) Pyridine carboxamide compounds for inhibiting NAV1.8
AU2006272837B2 (en) N-(arylamino)-sulfonamide inhibitors of MEK
JP2011517689A5 (https=)
KR101678255B1 (ko) 치환 아미드 화합물
JP2004536112A5 (https=)
CA2803118C (en) Sulfonamide derivatives as nav 1.7 inhibitors
RU2004100839A (ru) Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
CA3025887C (en) Sulfonamide compound or salt thereof
JP2008524244A5 (https=)
US9381177B2 (en) Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
WO2009112445A1 (en) Method of increasing cellular phosphatidyl choline by dgat1 inhibition
JP2008540574A5 (https=)
WO2007041365B1 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
JP2006515858A5 (https=)
JP2005522438A5 (https=)
JP2006523234A5 (https=)
JP2006508061A5 (https=)
KR101352217B1 (ko) 술폰아미드 화합물 또는 그의 염
KR20130098155A (ko) 치환된 2,3-디히드로이미다조[1,2-c]퀴나졸린-함유 조합물
RU2013102401A (ru) Анеллированные производные пиридина
JP2009537542A5 (https=)
JP2008545686A5 (https=)
EP2785714A1 (en) Improved modulators of hec1 activity and methods therefor
RU2007106037A (ru) Производные пиримидисульфонамида в качестве модуляторов рецепторов хемокинов